IOVANCE BIOTHERAPEUTICS, INC. 4

Iovance Biotherapeutics CFO Corleen M. Roche had 49,995 RSUs vest into common stock on August 6, 2026, with 21,238 shares withheld for taxes, resulting in 100,005 shares owned directly.

On August 6, 2026, Corleen M. Roche, Chief Financial Officer of Iovance Biotherapeutics, Inc., had 49,995 restricted stock units vest, which were converted into an equivalent number of shares of common stock. To cover mandatory tax withholding on this vesting, 21,238 shares were withheld by the issuer at an implied price of $6.21 per share, leaving her with 28,757 net new common shares from this RSU event. Following these transactions, Roche directly held 100,005 shares of Iovance common stock. The transactions are characterized as routine equity compensation vesting and associated tax withholding, not open-market purchases or sales.

Filing Facts

CIK

1425205

Ticker

IOVA

Form

4

Source Type

fda

Accession

0001104659-26-093482

Alert Tier

5